

DRUG SAFETY SYMPOSIUM

Advancing Excellence in Pharmaceutical Vigilance, Regulatory Affairs and Quality Assurance

DATE: 14-15 February 2024 | VENUE: Holiday Inn & Suites, Dubai Science Park, Dubai

What is Pharmacovigilance?

Pharmacovigilance is the science and practice of monitoring, assessing, understanding, and preventing adverse effects or any other drug-related problems associated with the use of pharmaceutical products. It plays a crucial role in ensuring the safety and efficacy of drugs and medical products throughout their lifecycle, from development and clinical trials to post-market surveillance.

At the forefront of advancing drug safety, the maiden edition of **Drug Safety Symposium** is dedicated to upholding the highest standards through rigorous practices in pharmacovigilance, regulatory compliance, and quality assurance. Our esteemed **Conference and Masterclass** format serves as premier gathering, offering a dynamic platform for attendees to delve into the latest industry trends, stay abreast of regulatory changes, and unearth innovative solutions propelling the pharmaceutical industry into the future.

Committed to excellence, we foster an environment conducive to meaningful discussions, knowledge sharing, and collaboration. Our goal is to empower participants with insights that transcend traditional boundaries, ensuring a transformative and enriching experience. Join us as we navigate the evolving landscape of drug safety, shaping the future of pharmaceuticals through expertise, exploration, and collaboration.

Reasons to Attend

- Critically appraise the founding principles of pharmacovigilance and landmark cases effecting change to recent drug safety issue
- Explain key operational drug safety definitions
- Demonstrate good pharmacovigilance practice and locate key sources of information and documentation
- Critically discuss issues associated with global pharmacovigilance
- Analyse the stages of drug development in terms of drug safety assessment and benefit risk
- Critically explain the strengths and weakness of pharmacovigilance reporting systems
- Identify and predict future challenges in drug safety and pharmacovigilance

WHO SHOULD ATTEND

- Global QPPVs / Deputies
- QPPV Office managers

- Heads of Pharmacovigilance
- Heads of Pharmacovigilance Technologies
- Drug Safety Managers and Leaders

List of professionals who should consider attending a PV conference, along with their respective departments or designations:

Pharmacovigilance Professionals:

- Pharmacovigilance Officers
- Drug Safety Specialists
- Pharmacovigilance Managers
- Medical Safety Officers
- Regulatory Affairs Specialists (with a focus on PV)

Regulatory Affairs Professionals:

- Regulatory Affairs Managers
- Regulatory Affairs Specialists
- Regulatory Compliance Managers

Quality Assurance and Compliance Teams:

- Quality Assurance Managers
- Compliance Officers
- Auditors

Clinical Research and Development Teams:

- Clinical Research Managers
- Clinical Project Managers
- Clinical Research Associates

Pharmaceutical Executives:

CEOs, Managing Directors, General Managers

Patient Safety Officers

Representatives of Patient Advocacy Organizations

Regulatory Authorities Representatives: Officials from health regulatory agencies responsible for drug safety and surveillance

Clinical Trial Managers: Professionals overseeing clinical trials with a focus on safety monitoring

Independent consultants providing PV expertise

Drug Manufacturing and Quality Control Specialists: Professionals involved in ensuring drug quality and safety during manufacturing